IL257732B - 1-((6-Methoxynaphthalen-2-yl)methyl)-4-(3,3,3-trifluoropropanoyl)-octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalate and synthesis His - Google Patents

1-((6-Methoxynaphthalen-2-yl)methyl)-4-(3,3,3-trifluoropropanoyl)-octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalate and synthesis His

Info

Publication number
IL257732B
IL257732B IL257732A IL25773218A IL257732B IL 257732 B IL257732 B IL 257732B IL 257732 A IL257732 A IL 257732A IL 25773218 A IL25773218 A IL 25773218A IL 257732 B IL257732 B IL 257732B
Authority
IL
Israel
Prior art keywords
methanopyrrolo
methoxynaphthalen
propanoyl
octahydro
pivalate
Prior art date
Application number
IL257732A
Other languages
English (en)
Hebrew (he)
Other versions
IL257732A (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL257732A publication Critical patent/IL257732A/en
Publication of IL257732B publication Critical patent/IL257732B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
IL257732A 2015-09-04 2018-02-26 1-((6-Methoxynaphthalen-2-yl)methyl)-4-(3,3,3-trifluoropropanoyl)-octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalate and synthesis His IL257732B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214734P 2015-09-04 2015-09-04
US201562214727P 2015-09-04 2015-09-04
PCT/US2016/049877 WO2017040767A1 (en) 2015-09-04 2016-09-01 Therapeutic compounds for pain and synthesis thereof

Publications (2)

Publication Number Publication Date
IL257732A IL257732A (en) 2018-04-30
IL257732B true IL257732B (en) 2020-11-30

Family

ID=58188341

Family Applications (5)

Application Number Title Priority Date Filing Date
IL257732A IL257732B (en) 2015-09-04 2018-02-26 1-((6-Methoxynaphthalen-2-yl)methyl)-4-(3,3,3-trifluoropropanoyl)-octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalate and synthesis His
IL257740A IL257740A (en) 2015-09-04 2018-02-26 Medicinal compounds for pain and their synthesis
IL257734A IL257734B (en) 2015-09-04 2018-02-26 -(cyclopropylmethyl)-4-(3,3,3-trifluoropropanoyl)octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-ylpivalates and their synthesis
IL257737A IL257737B2 (en) 2015-09-04 2018-02-26 Methanopyrrolo-pyridine-carboxylate based therapeutic compounds and synthesis thereof
IL257735A IL257735B (en) 2015-09-04 2018-02-26 4-(3,3,3-trifluoropropanoyl)octahydro-h1-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalates and their synthesis

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL257740A IL257740A (en) 2015-09-04 2018-02-26 Medicinal compounds for pain and their synthesis
IL257734A IL257734B (en) 2015-09-04 2018-02-26 -(cyclopropylmethyl)-4-(3,3,3-trifluoropropanoyl)octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-ylpivalates and their synthesis
IL257737A IL257737B2 (en) 2015-09-04 2018-02-26 Methanopyrrolo-pyridine-carboxylate based therapeutic compounds and synthesis thereof
IL257735A IL257735B (en) 2015-09-04 2018-02-26 4-(3,3,3-trifluoropropanoyl)octahydro-h1-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalates and their synthesis

Country Status (11)

Country Link
US (9) US9994572B2 (enExample)
EP (5) EP3344626B9 (enExample)
JP (5) JP6868008B2 (enExample)
CN (5) CN109153679B (enExample)
CA (5) CA2997541C (enExample)
DK (4) DK3344614T5 (enExample)
ES (4) ES2812233T3 (enExample)
IL (5) IL257732B (enExample)
MA (1) MA45011A (enExample)
TW (11) TWI713879B (enExample)
WO (5) WO2017040767A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6868008B2 (ja) * 2015-09-04 2021-05-12 ヤンセン ファーマシューティカ エヌ．ベー． 疼痛のための治療化合物及びその合成

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469781A (en) * 1974-06-10 1977-04-06 Boehringer Sohn Ingelheim Production of scopine
US4232026A (en) * 1978-07-20 1980-11-04 Merck & Co., Inc. Diazaditwistanes, and pharmaceutical compositions for treating pain in warm blooded animals containing them
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5422354A (en) * 1990-07-23 1995-06-06 Pfizer Inc Quinuclidine derivatives
DE553264T1 (de) 1990-10-05 1994-04-28 Wayne M Barnes Thermostabile dna polymerase.
US6432976B1 (en) * 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
DE10050994A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
ATE435862T1 (de) * 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
CA2539811A1 (en) * 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
WO2007024814A1 (en) * 2005-08-22 2007-03-01 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008104955A1 (en) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
TW200840569A (en) 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
WO2009124755A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
CN101768158B (zh) * 2010-01-04 2013-05-29 南昌弘益科技有限公司 噻托溴铵无水物及其制备方法
CN102579458A (zh) * 2012-03-08 2012-07-18 冀中能源峰峰集团有限公司总医院 缓解静点药物所致疼痛和防治静脉炎的药品配方
JP6102122B2 (ja) * 2012-08-24 2017-03-29 ソニー株式会社 画像処理装置および方法、並びにプログラム
BR112015006029B1 (pt) * 2012-09-18 2022-01-25 Heptares Therapeutics Limited Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias
TW201444849A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI627174B (zh) * 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
KR20160115503A (ko) * 2015-03-27 2016-10-06 차의과학대학교 산학협력단 만성 골수성 백혈병 암 줄기세포의 성장 또는 증식 억제용 조성물 및 이의 스크리닝 방법
GB201505654D0 (en) * 2015-04-01 2015-05-13 Nordic Bioscience As Immunoassay for collagen type VI sequence
GB201505701D0 (en) * 2015-04-02 2015-05-20 Byotrol Plc Anti-microbial composition
JP6868008B2 (ja) * 2015-09-04 2021-05-12 ヤンセン ファーマシューティカ エヌ．ベー． 疼痛のための治療化合物及びその合成

Also Published As

Publication number Publication date
JP6868008B2 (ja) 2021-05-12
CA2997430A1 (en) 2017-03-09
CN108349934B (zh) 2021-10-22
ES2809703T3 (es) 2021-03-05
JP2018527356A (ja) 2018-09-20
DK3344627T5 (da) 2021-08-30
US10351566B2 (en) 2019-07-16
WO2017040770A1 (en) 2017-03-09
TW201811786A (zh) 2018-04-01
ES2812233T9 (es) 2022-02-18
DK3344627T3 (da) 2020-07-20
EP3344614A1 (en) 2018-07-11
US20170066760A1 (en) 2017-03-09
ES2812233T3 (es) 2021-03-16
US10040796B2 (en) 2018-08-07
ES2807901T3 (es) 2021-02-24
WO2017040778A1 (en) 2017-03-09
EP3344614B9 (en) 2021-07-28
IL257735A (en) 2018-04-30
JP2018527355A (ja) 2018-09-20
CA2997541C (en) 2022-01-11
TW201833110A (zh) 2018-09-16
DK3344626T5 (da) 2021-09-06
US10351565B2 (en) 2019-07-16
WO2017040764A1 (en) 2017-03-09
WO2017040772A9 (en) 2019-03-07
CA2997543A1 (en) 2017-03-09
CA2997543C (en) 2022-07-19
US10040795B2 (en) 2018-08-07
ES2808048T3 (es) 2021-02-25
IL257737B (en) 2022-10-01
ES2809703T9 (es) 2022-01-24
TWI683815B (zh) 2020-02-01
US20170066769A1 (en) 2017-03-09
US9994572B2 (en) 2018-06-12
EP3344627B1 (en) 2020-07-01
TW201722955A (zh) 2017-07-01
EP3344628B1 (en) 2020-07-15
US10766898B2 (en) 2020-09-08
US20180327406A1 (en) 2018-11-15
TWI654188B (zh) 2019-03-21
CN108495854B (zh) 2021-10-15
TWI686393B (zh) 2020-03-01
TW201722953A (zh) 2017-07-01
IL257737B2 (en) 2023-02-01
TWI672303B (zh) 2019-09-21
TWI636054B (zh) 2018-09-21
WO2017040772A1 (en) 2017-03-09
CN108290890A (zh) 2018-07-17
MA45011A (fr) 2021-06-02
CN109071540A (zh) 2018-12-21
JP6736661B2 (ja) 2020-08-05
DK3344614T5 (da) 2021-08-30
CA2997430C (en) 2021-05-11
US20170066768A1 (en) 2017-03-09
JP6736660B2 (ja) 2020-08-05
CA2997501C (en) 2022-05-10
TW201722954A (zh) 2017-07-01
TWI695836B (zh) 2020-06-11
DK3344628T3 (da) 2020-08-03
CA2997541A1 (en) 2017-03-09
US20170066770A1 (en) 2017-03-09
TWI641608B (zh) 2018-11-21
EP3344614A4 (en) 2019-03-27
ES2808048T9 (es) 2022-02-01
JP2018526388A (ja) 2018-09-13
TWI713879B (zh) 2020-12-21
CN109071540B (zh) 2021-06-04
EP3344628A1 (en) 2018-07-11
CN108495854A (zh) 2018-09-04
CA2997545A1 (en) 2017-03-09
EP3344626B9 (en) 2021-08-11
IL257735B (en) 2022-01-01
US20180291024A1 (en) 2018-10-11
TW201843153A (zh) 2018-12-16
EP3344614B1 (en) 2020-07-08
US20190112311A1 (en) 2019-04-18
TW201819381A (zh) 2018-06-01
IL257734B (en) 2021-07-29
TW201716409A (zh) 2017-05-16
CA2997501A1 (en) 2017-03-09
DK3344626T3 (da) 2020-07-27
EP3344627A1 (en) 2018-07-11
JP2018531907A (ja) 2018-11-01
IL257734A (en) 2018-04-30
US10358448B2 (en) 2019-07-23
DK3344628T5 (da) 2021-07-26
EP3344627B9 (en) 2021-08-04
EP3344627A4 (en) 2019-03-27
EP3344626A1 (en) 2018-07-11
CN108349934A (zh) 2018-07-31
EP3344629A1 (en) 2018-07-11
US20170066767A1 (en) 2017-03-09
TWI707854B (zh) 2020-10-21
US20180327405A1 (en) 2018-11-15
EP3344626B1 (en) 2020-07-08
CA2997545C (en) 2022-01-11
EP3344626A4 (en) 2019-03-27
WO2017040767A1 (en) 2017-03-09
IL257740A (en) 2018-04-30
JP6736659B2 (ja) 2020-08-05
CN109153679B (zh) 2022-04-08
TWI663167B (zh) 2019-06-21
CN109153679A (zh) 2019-01-04
TW201835082A (zh) 2018-10-01
US10155762B2 (en) 2018-12-18
EP3344628A4 (en) 2019-03-27
EP3344628B9 (en) 2021-06-30
JP2018526387A (ja) 2018-09-13
CN108290890B (zh) 2021-08-06
TW201920176A (zh) 2019-06-01
TWI639597B (zh) 2018-11-01
US10040797B2 (en) 2018-08-07
EP3344629A4 (en) 2019-03-27
JP6639651B2 (ja) 2020-02-05
IL257732A (en) 2018-04-30
IL257737A (en) 2018-04-30
TW201722951A (zh) 2017-07-01
ES2807901T9 (es) 2022-01-31
DK3344614T3 (da) 2020-07-27

Similar Documents

Publication Publication Date Title
SMT202200122T1 (it) Derivato di benzazepina, metodo di preparazione, composizione farmaceutica e suo uso
IL258082B (en) History of benzaimidazole and pharmaceutical preparations containing them
EP3312184A4 (en) PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
IL254124A0 (en) New 3-indole-transformed histories, medicinal preparations and methods of use
IL254714A0 (en) History of quinoline and pharmaceutical preparations containing them
PL3287443T3 (pl) 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca
IL258160B (en) Biaryl derivatives, pharmaceutical preparations containing them and their uses
IL243226B (en) History of pyrazole, their preparation and pharmaceutical preparations containing them
IL250422A0 (en) History of pyrrolidinone, and pharmaceutical preparations containing them
EP3073998A4 (en) Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
IL265970B (en) Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine
IL246545B (en) History of 3-hydroxy-3-[(cyclopropylmethoxy)-4-(fluoro)phenyl]-4-(h1- 3,2,1-triazol-1-yl)-butane and pharmaceutical preparations containing them
IL273339A (en) Griseofulbin compound and its medical use
EP3381925A4 (en) Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
EP3299016A4 (en) USE OF OXIRACETAM DEXTROGYRE IN THE PHARMACEUTICAL FIELD
PL3320903T3 (pl) Kompozycja farmaceutyczna zawierająca amlodypinę, walsartan i rosuwastatynę
PL3521281T3 (pl) Pochodna 1-[(pirydyn-3-ylosulfonylo)-1h-pirol-3-ilo]metanaminy i kompozycja farmaceutyczna oraz ich zastosowanie
IL252897A0 (en) Indanyl compounds, pharmaceutical preparations and their medical uses
IL248773B (en) History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them
EP3162802A4 (en) 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same
EP3284743A4 (en) Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
SG11201610636VA (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
EP3327021A4 (en) Janus kinase 1 selective inhibitor and pharmaceutical use thereof
ZA201703015B (en) Solid pharmaceutical composition comprising amlodipine and losartan
IL257732B (en) 1-((6-Methoxynaphthalen-2-yl)methyl)-4-(3,3,3-trifluoropropanoyl)-octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalate and synthesis His

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed